Results for tag: "Kengreal"

Kengreal is a cardiovascular drug developed by Merck & Co. It is a direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Kengreal is also used to treat and prevent deep vein thrombosis and pulmonary embolism. It is available in both oral and injectable forms. Kengreal is part of a larger market of cardiovascular drugs, which includes anticoagulants, antiplatelet agents, and other drugs used to treat and prevent cardiovascular diseases. These drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular events. They are also used to treat and prevent conditions such as hypertension, coronary artery disease, and congestive heart failure. The Kengreal market includes companies such as Merck & Co., Bristol-Myers Squibb, Pfizer, AstraZeneca, and Sanofi. These companies are involved in the development, manufacture, and marketing of Kengreal and other cardiovascular drugs. Show Less Read more